ArticleFrontiers in nutrition2026
Isolation and characterization of extracellular vesicles from human milk for potential use as a dietary supplement in clinical research with preterm infants.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Goat and cow-milk based infant formulas contain extracellular vesicles with different miRNA and protein cargo.Current research in food science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/objectives: Human milk (HM) is the gold standard for neonatal nutrition, providing essential macronutrients and bioactive compounds that promote immune and gastrointestinal development. Among these components, HM-derived extracellular vesicles (HMEVs) are emerging as key mediators of intestinal maturation and protection against necrotizing enterocolitis (NEC). HMEVs carry miRNAs, proteins, and bioactive lipids that resist digestion and modulate critical signaling pathways in the immature gut, making them particularly relevant for preterm infants. Methods: This study describes the development and adaptation of a robust, scalable workflow for isolating HMEVs from donor HM for potential use as a nutritional supplement. An initial laboratory-scale isolation protocol was successfully scaled up to a sterile, clinically compatible process. Key modifications included increasing ultracentrifugation speed, eliminating filtration, and replacing phosphate-buffered saline (PBS) with a resuspension medium suitable for nutritional applications. Results: The scaled procedure increased the processed milk volume from 25 mL to 63 mL while reducing the HMEVs isolation time from 14 hs to 7.7 h. Tunable Resistive Pulse Sensing (TRPS) and ExoView Conclusions: This optimized and scalable method enables the safe and efficient isolation of HMEVs for use in neonatal nutritional supplements. These findings establish methodological groundwork for future translational studies of milk-derived EVs aimed at supporting intestinal development and immune protection, and potentially reducing the risk of NEC in preterm infants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.